Annovis Bio Appoints Mark Guerin as CFO to Support Late-Stage Neurodegenerative Drug Development

Annovis Bio Inc. has appointed Mark Guerin as Chief Financial Officer to provide financial leadership as the company advances its lead drug candidate buntanetap through late-stage clinical trials for neurodegenerative diseases. Guerin brings extensive financial management experience from previous roles including CFO of Onconova Therapeutics, now Traws Pharma, where he oversaw multiple financings and a merger that formed the new entity. His background also includes senior finance positions at Cardiokine, Barrier Therapeutics, and Coopers & Lybrand.

The appointment comes at a critical time for Annovis Bio as the company works to replicate buntanetap's early success in registrational studies. Guerin expressed enthusiasm about supporting the company's mission to deliver solutions for patients suffering from Alzheimer's and Parkinson's disease. His financial expertise will be instrumental in managing the complex financial requirements of late-stage clinical development and potential commercialization pathways.

Annovis Bio maintains its corporate information at https://www.annovisbio.com where investors and stakeholders can access company updates. The company focuses on developing innovative therapies that address neurodegeneration in diseases such as Alzheimer's and Parkinson's, with buntanetap representing their most advanced clinical candidate. The drug platform company's approach to treating neurodegenerative conditions has generated significant interest in the biomedical community.

Guerin's appointment strengthens the executive team's financial capabilities during a period of intensive clinical development activity. His experience with multiple financings and corporate transactions positions him well to support Annovis Bio's strategic objectives as the company progresses toward potential regulatory milestones. The financial leadership transition occurs as the company prepares for important clinical trial readouts and potential regulatory interactions.

The company's newsroom at https://ibn.fm/ANVS provides ongoing updates about Annovis Bio's development programs and corporate activities. This financial appointment represents a strategic move to bolster the company's leadership team as it navigates the complex landscape of late-stage drug development for neurodegenerative conditions that affect millions of patients worldwide.